Table 2.
Roles of chemokine system as prognostic factors in cancers.
| Chemokines/Receptors | Cancer Types | Sites of Expression | Study Types | References |
|---|---|---|---|---|
| Good prognostic markers | ||||
| CCL2 | Non-small cell lung cancer (NSCLC) | Tissue | Retrospective | [153] |
| CCL14 | Hepatocellular carcinoma (HCC) | Tissue | Retrospective | [105] |
| CXCL10 | Esophageal squamous cell carcinoma | Tissue | Prospective | [195] |
| CX3CL1/CX3CR1 | HCC | Tissue | Prospective | [211] |
| CX3CL1 | Gastric adenocarcinoma | Tissue | Prospective | [210] |
| XCL1 | Acute lymphoblastic leukemia | Serum | Prospective | [216] |
| Poor prognostic markers | ||||
| CCL2/CCR2 | Diffuse large B cell lymphoma (DLBCL) | Tissue | Prospective | [160] |
| CCL5 | Breast cancer (BC) | Serum | Prospective | [81] |
| Stage II BC | Tissue | Prospective | [162] | |
| CCL20 | Colorectal cancer (CRC) | Tissue | Prospective | [167] |
| CCL20/CCR6 | HCC | Tissue | Prospective | [169] |
| CCL21/CCR7 | Colorectal liver metastasis | Tissue | Prospective | [169] |
| CCR7 | Solid tumors | Tissue | Meta-analysis | [178] |
| CXCL1 | Various cancers | Tissue, urine, serum | Meta-analysis | [181] |
| CXCL8 | CRC | Tissue | Prospective | [167] |
| CRC | Serum | Prospective | [188] | |
| Cervical Cancer | Tissue | Prospective | [189] | |
| Lung adenocarcinoma | Tissue | Prospective | [190] | |
| CXCL10 | DLBCL | Serum | Prospective-retrospective | [196] |
| CXCL12 | Esophageal cancer | Tissue | Prospective | [202] |
| CXCR4 | Acute myelogenous leukemia (AML) | AML cells | Prospective | [203] |
| Early BC | Tissue | Prospective-retrospective | [205] | |
| BC | Tissue | Meta-analysis | [204] | |
| HCC | Circulation and/or tissues | Meta-analysis | [206] | |
| NSCLC | Tissue | Meta-analysis | [207] | |
| CX3CL1/CX3CR1 | Pancreatic ductal adenocarcinoma | Tissue | Retrospective | [213] |
For detailed information, please see the text.